Trial NCT05671653

View at ClinicalTrials.gov 
Org. Study IDs: C3991040

Last trial update was posted on 2023-12-26

MeSH Interventions

Semaglutide

MeSH Conditions

Obesity

Other Conditions


Stopping Reasons

The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID